Advertisement

Switch from Sodium Phenylbutyrate to Glycerol Phenylbutyrate Improved Metabolic Stability in an Adolescent with Ornithine Transcarbamylase Deficiency

  • Alexander Laemmle
  • Tamar Stricker
  • Johannes HäberleEmail author
Case Report
Part of the JIMD Reports book series (JIMD, volume 31)

Abstract

A male patient, born in 1999, was diagnosed with ornithine transcarbamylase deficiency as neonate and was managed with a strict low-protein diet supplemented with essential amino acids, l-citrulline, and l-arginine as well as sodium benzoate. He had an extensive history of hospitalizations for hyperammonemic crises throughout childhood and early adolescence, which continued after the addition of sodium phenylbutyrate in 2009. In December 2013 he was switched to glycerol phenylbutyrate, and his metabolic stability was greatly improved over the following 7 months prior to liver transplant.

Keywords

Glycerol phenylbutyrate Hyperammonemia Ornithine transcarbamylase deficiency Sodium phenylbutyrate Urea cycle disorder 

Notes

Acknowledgment

Glycerol phenylbutyrate (Ravicti®) was provided free of charge on a compassionate use basis by Hyperion Therapeutics. Medical writing assistance was provided by Jacqueline Wu, PhD, with funding provided by Horizon Pharma (current license holder of Ravicti®), but this had no influence on the content of the report or on interpretation of data. Alexander Laemmle was supported by competitive research grants from the EMDO Foundation Zurich (Grant 851 to JH and AL) and by the Children’s Research Center – University Children’s Hospital Zurich (Grant 10511 to AL) while working on this study. The work on urea cycle disorders is supported by the Swiss National Science Foundation (grant 310030_153196 to JH).

References

  1. Batshaw ML et al (1982) Treatment of inborn errors of urea synthesis: activation of alternative pathways of waste nitrogen synthesis and excretion. N Engl J Med 306(23):1387–1392CrossRefPubMedGoogle Scholar
  2. Batshaw ML et al (2014) A longitudinal study of urea cycle disorders. Mol Genet Metab 113(1–2):127–130CrossRefPubMedPubMedCentralGoogle Scholar
  3. Berry SA et al (2014) Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes. Mol Genet Metab 112(1):17–24CrossRefPubMedPubMedCentralGoogle Scholar
  4. Brusilow SW (1991) Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr Res 29(2):147–150CrossRefPubMedGoogle Scholar
  5. Brusilow SW, Maestri NE (1996) Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv Pediatr 43:127–170PubMedGoogle Scholar
  6. Diaz GA et al (2013) Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. Hepatology 57(6):2171–2179CrossRefPubMedPubMedCentralGoogle Scholar
  7. Gropman AL et al (2008) 1H MRS identifies symptomatic and asymptomatic subjects with partial ornithine transcarbamylase deficiency. Mol Genet Metab 95(1–2):21–30CrossRefPubMedPubMedCentralGoogle Scholar
  8. Häberle J et al (2012) Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis 7:32CrossRefPubMedPubMedCentralGoogle Scholar
  9. Lee B et al (2010) Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. Mol Genet Metab 100(3):221–228CrossRefPubMedPubMedCentralGoogle Scholar
  10. Lichter-Konecki U et al (2011) Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate. Mol Genet Metab 103(4):323–329CrossRefPubMedPubMedCentralGoogle Scholar
  11. MacDonald A et al (2012) Adherence issues in inherited metabolic disorders treated by low natural protein diets. Ann Nutr Metab 61(4):289–295CrossRefPubMedGoogle Scholar
  12. McGuire BM et al (2010) Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. Hepatology 51(6):2077–2085CrossRefPubMedPubMedCentralGoogle Scholar
  13. Monteleone JP et al (2013) Population pharmacokinetic modeling and dosing simulations of nitrogen-scavenging compounds: disposition of glycerol phenylbutyrate and sodium phenylbutyrate in adult and pediatric patients with urea cycle disorders. J Clin Pharmacol 53(7):699–710CrossRefPubMedPubMedCentralGoogle Scholar
  14. Smith W et al (2013) Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate. J Pediatr 162(6):1228–1234, 1234 e1CrossRefPubMedPubMedCentralGoogle Scholar
  15. Summar ML et al (2008) Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes. Acta Paediatr 97(10):1420–1425CrossRefPubMedPubMedCentralGoogle Scholar
  16. Tuchman M et al (2008) Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Genet Metab 94(4):397–402CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© SSIEM and Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Alexander Laemmle
    • 1
  • Tamar Stricker
    • 1
  • Johannes Häberle
    • 1
    Email author
  1. 1.Division of Metabolism and Children’s Research Center (CRC)University Children’s HospitalZurichSwitzerland

Personalised recommendations